Relay Therapeutics (RLAY) said Wednesday updated interim clinical data from its first-in-human study of RLY-2608 in combination with fulvestrant showed "clinically meaningful" progression-free survival in patients with locally advanced or metastatic breast cancer.
The updated data showed a median progression-free survival of 11.4 months in second-line patients who received a 600-milligram dosage of RLY-2608 twice a day plus fulvestrant, the company said, adding its RLY-2608 and fulvestrant arm enrolled 118 patients, and was "generally well tolerated."
The company plans to start a pivotal study of RLY-2608 plus fulvestrant in 2025, with data from the phase 1/2 study to be released the same year.
Relay Therapeutics shares were up nearly 6% in recent Wednesday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。